# Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.

> **NCT05176002** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fujian Medical University Union Hospital** · enrollment: 25 (estimated)

## Conditions studied

- Esophageal Neoplasm
- Immunotherapy
- Radiotherapy

## Interventions

- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT05176002
- **Lead sponsor:** Fujian Medical University Union Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-10
- **Primary completion:** 2023-09-30
- **Final completion:** 2026-11
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05176002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05176002, "Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05176002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*